Corvus Pharmaceuticals
CRVS
61 hedge funds and large institutions have $219M invested in Corvus Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
7% more funds holding
Funds holding: 57 → 61 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.06% less ownership
Funds ownership: 88.75% → 87.69% (-1.1%)
23% less capital invested
Capital invested by funds: $284M → $219M (-$65M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.04M |
| 2 |
BlackRock
New York
|
+$870K |
| 3 |
Renaissance Technologies
New York
|
+$720K |
| 4 |
CI
Cowen Inc
New York
|
+$543K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$438K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.59M |
| 2 |
Millennium Management
New York
|
-$3.08M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$990K |
| 4 |
Goldman Sachs
New York
|
-$390K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$146K |
CRVS Hedge Fund Activity: Q3 2018 in Review
61 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q3 2018, worth a combined $219M — down 23% from $284M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CRVS positions and 4 closed out — a net gain of 4 holders — while 26 added to existing stakes and 14 trimmed.
The largest buyer was Dimensional Fund Advisors, adding an estimated $1.04M. The largest seller was Fidelity Investments, cutting an estimated $4.59M.
- 61 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q3 2018, up from 57 in Q2 2018.
- Funds reported $219M of Corvus Pharmaceuticals stock for Q3 2018, down 23% quarter-over-quarter.
- 8 funds opened new Corvus Pharmaceuticals positions in Q3 2018 and 4 closed out, a net change of +4 holders.
- The largest Corvus Pharmaceuticals buyer in Q3 2018 was Dimensional Fund Advisors, an estimated $1.04M added.
- The largest Corvus Pharmaceuticals seller in Q3 2018 was Fidelity Investments, an estimated $4.59M sold.
Based on aggregated 13F filings for Q3 2018.